Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets

TQB3201 is an orally administered targeted protein chimera (PROTAC) drug in which one end of the drug is attached to a ligand that binds to Androgen Receptor (AR) and the other end to a ligand of E3 ligase (CRBN) via a linker. The phase I phase of this trial aims to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQB3201 tablets for the treatment of advanced prostate cancer.

NCT Number	NCT07172126
Lead Sponsor	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions	Metastatic Castration-resistant Prostate Cancer
Enrollment	291 participants
Start Date	2025-09
Primary Completion	2027-04 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2025-09-15